Protein-enriched Platelet-Rich Plasma (PEF<SUB>PRP</SUB>) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study

Laura Mazzucco; Valeria Balbo; Simona Martinotti; Elia Ranzato; Mauro Patrone; Marcello Manfredi; Roberto Guaschino

doi:doi:10.11648/j.frontiers.20210101.11

| Peer-Reviewed

Protein-enriched Platelet-Rich Plasma (PEF_PRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study

Laura Mazzucco, Valeria Balbo, Simona Martinotti, Elia Ranzato, Mauro Patrone, Marcello Manfredi, Roberto Guaschino

Published in Frontiers (Volume 1, Issue 1)

Received: 28 December 2020 Accepted: 8 January 2021 Published: 22 January 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component Protein-Enriched Filtered PRP (PEF_PRP) obtained through the ultrafiltration of low-concentration PRP and compared these effects with those of a standard PRP and other blood components preparation. Method: PEF_PRP is a plasma enriched obtained by ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and other blood components preparation. Result and Conclusion: PEF_PRP provides a high concentration of proteins which have an important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration.

Published in	Frontiers (Volume 1, Issue 1)
DOI	10.11648/j.frontiers.20210101.11
Page(s)	1-6
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Platelet-rich Plasma, Plasma Proteins, Ultrafiltration, Growth Factors

References

[1]	Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet®, RegenPRP-Kit®, Plateltex® and one manual procedure. Vox Sang 2009; 97: 110-8.
[2]	Mazzucco L, Balbo V, Guaschino R. "Reasonable compromise" to define the quality standards of platelet concentrate for non-transfusion use (CPunT). Transfus Apher Sci 2012; 47: 207-211.
[3]	Tsay RC, Vo J, Burke A, et al. Differential growth factor retention by platelet-rich plasma composites. J Oral Maxillofac Surg 2005; 63: 521-528.
[4]	Han J, Meng HX, Tang JM, et al. The effect of different platelet-rich plasma concentrations on proliferation and differentiation of human periodontal ligament cells in vitro. Cell Prolif 2007; 40: 241-252.
[5]	Russell RP, Apostolakos J, Hirose T, et al. Variability of platelet-rich plasma preparations. Sports Med Arthrosc Rev 2013; 21: 186-190.
[6]	Anitua A, Alkhraisat G, Orive G, et al. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release 2012; 157: 29-38.
[7]	Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy-future or trend? Arthritis Re Ther 2012; 14: 219.
[8]	Anitua E, Troya M, Zalduendo M, et al. Personalized plasma-based medicine to treat age-related diseases. Materials Science and Engineering 2016; 74: 459-464.
[9]	Jain KK. Role of biological therapies in the development of personalized medicine. Expert Opin Biolo Ther 2012; 12: 1-5.
[10]	Milano G, Sanchet M, Jo CH, et al. Platelet-rich plasma in orthopaedic sports medicine: state of the art. BMJ 2019; 4: 188-195.
[11]	Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 638-646.
[12]	Dohan Ehrenfest DM, Bielecki T, Mishra A, et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol 2012; 13: 1131-1137.
[13]	Nurden AT. The biology of the platelet with special reference to inflammation, wound healing and immunity. Front Biosci 2018; 23: 726-751.
[14]	Karimi K, Rockwell H. The benefits of platelet-rich fibrin. Facial Plast Surg Clin North Am 2019; 27: 331-340.
[15]	Zimmermann R, Arnold D, Strasser E, et al. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang 2003; 85: 283-289.
[16]	Mazzucco L, Borzini P, Gope R. Platelet-derived factors involved in tissue repair-from signal to function. Transfus Med Rev 2010; 24: 218-234.
[17]	Gura V, Ronco C, Nalesso F, et al. A wearable hemofilter for continuous ambulatory ultrafiltration. Kidney Int 2008; 4: 497-502.
[18]	Ronco C. Hemodialfiltration: technical and clinical Issues. Blood Purif 2015; 40: 2-11
[19]	Noh KC, Liu XN, Zhuan Z, et al. Leukocyte-poor platelet-rich plasma-derived growth factors enhance human fibroblast proliferation in vitro. Clean Orthop Surg 2018; 10: 240-247
[20]	Van der Bijl I, Vlig M, Middelkoop E, et al. Allogeneic platelet-rich plasma (PRP) is superior to platelets or plasma alone in stimulating fibroblast proliferation and migration, angiogenesis, and chemotaxis as relevant processes for wound healing. Transfusion 2019; 59: 3492-3500.
[21]	Muraglia A, Nguyen VT, Nardini M, et al. Culture medium supplements derived from human platelet and plasma: cell commitment and proliferation support. Front Bioeng Biotechnol 2017; 20: 55-66.
[22]	Hung Y, Elder MJ, Rawstron JA, et al. A retrospective crossover study of autologous and allogeneic serum eye drops for the management of ocular surface disease. Transfus Med 2019; 29: 69-71.
[23]	Kawase T, Nagata M, Okuda K, et al. Platelet-rich fibrin extract: a promising fetal bovine serum alternative in explant cultures of human periosteal sheets for regenerative therapy. Int J Mol Sci 2019; 20: 1053.
[24]	Zernii EY, Baksheeva VE, Iani EV, et al. Therapeutic proteins for treatment of corneal epithelial detects. Curr Med Chem 2019; 26: 517-545.
[25]	Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface 2011; 8: 153-170.
[26]	Qiao J, An N, Ouyang X. Quantification of growth factors in different platelet concentrates. Platelets 2017; 28: 774-778.
[27]	Ziegler CG, Sloun RV, Gonzalez S, et al. Characterization of growth factors, cytokines, and chemokines in bone marrow concentrate and platelet-rich plasma. Am J Sport Med 2019; 47: 2174-2187
[28]	Brandi J, Manfredi M, Speziali G, et al. Proteomic approaches to decipher cancer cell secretome. Semin Cell Dev Biol 2018; 78: 93-101.
[29]	Cipriani V, Ranzato E, Balbo V, et al. Long-term effect of platelet lysate on primary fibroblasts highlighted with a proteomic approach. J Tissue Eng Regen Med 2009; 3: 531-538.
[30]	Andia I, Maffulli N. Blood-derived products for tissue repair/regeneration. Int J Mol Sci 2019; 20: 4581.
[31]	Kim SJ, Davis RP, Jenne CN. Platelets as modulators of inflammation. Semin Thromb Hemost 2018; 44: 91-101.
[32]	Borzini P, Mazzucco L. Platelet gels and releasates. Curr Opin Hematol 2005; 12: 473-479.
[33]	Lee HW, Choi KH, Kim JY, et al. Proteomic classification and identification of proteins related to tissue healing of platelet-rich plasma. Clin Orthop Surg 2020; 12: 120-129.
[34]	Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood 2015; 29: 153-162.
[35]	Olczyk P, Mencner L, Komosinska-Vassev K. The role of the extracellular matrix components in cutaneous wound healing. Biomed Res Int 2014; 11: 1-8.
[36]	Moss AJ, Scharma S, Brindle NP. Rational design and protein engineering of growth factors for regenerative medicine and tissue engineering. Biochem Soc Trans 2009; 37: 717-721.
[37]	Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39: 2135-2140.
[38]	Bretschneider H, Quade M, Lode A, et al. Characterization of naturally occurring bioactive factor mixtures for bone regeneration. Int J Mol Sci 2020; 21: 1412-1427.

Cite This Article

Plain Text BibTeX RIS

APA Style

Laura Mazzucco, Valeria Balbo, Simona Martinotti, Elia Ranzato, Mauro Patrone, et al. (2021). Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers, 1(1), 1-6. https://doi.org/10.11648/j.frontiers.20210101.11

Copy | Download

ACS Style

Laura Mazzucco; Valeria Balbo; Simona Martinotti; Elia Ranzato; Mauro Patrone, et al. Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers. 2021, 1(1), 1-6. doi: 10.11648/j.frontiers.20210101.11

Copy | Download

AMA Style

Laura Mazzucco, Valeria Balbo, Simona Martinotti, Elia Ranzato, Mauro Patrone, et al. Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers. 2021;1(1):1-6. doi: 10.11648/j.frontiers.20210101.11

Copy | Download

@article{10.11648/j.frontiers.20210101.11,
  author = {Laura Mazzucco and Valeria Balbo and Simona Martinotti and Elia Ranzato and Mauro Patrone and Marcello Manfredi and Roberto Guaschino},
  title = {Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study},
  journal = {Frontiers},
  volume = {1},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.frontiers.20210101.11},
  url = {https://doi.org/10.11648/j.frontiers.20210101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.frontiers.20210101.11},
  abstract = {Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component Protein-Enriched Filtered PRP (PEFPRP) obtained through the ultrafiltration of low-concentration PRP and compared these effects with those of a standard PRP and other blood components preparation. Method: PEFPRP is a plasma enriched obtained by ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and other blood components preparation. Result and Conclusion: PEFPRP provides a high concentration of proteins which have an important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study
AU  - Laura Mazzucco
AU  - Valeria Balbo
AU  - Simona Martinotti
AU  - Elia Ranzato
AU  - Mauro Patrone
AU  - Marcello Manfredi
AU  - Roberto Guaschino
Y1  - 2021/01/22
PY  - 2021
N1  - https://doi.org/10.11648/j.frontiers.20210101.11
DO  - 10.11648/j.frontiers.20210101.11
T2  - Frontiers
JF  - Frontiers
JO  - Frontiers
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2994-7197
UR  - https://doi.org/10.11648/j.frontiers.20210101.11
AB  - Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component Protein-Enriched Filtered PRP (PEFPRP) obtained through the ultrafiltration of low-concentration PRP and compared these effects with those of a standard PRP and other blood components preparation. Method: PEFPRP is a plasma enriched obtained by ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and other blood components preparation. Result and Conclusion: PEFPRP provides a high concentration of proteins which have an important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration.
VL  - 1
IS  - 1
ER  -

Copy | Download

Author Information

Laura Mazzucco

Transfusion Medicine, “SS. Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria, Italy
Valeria Balbo

Transfusion Medicine, “SS. Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria, Italy
Simona Martinotti

Department of Science and Technology Innovation, University of Piemonte Orientale, Alessandria, Italy
Elia Ranzato

Department of Science and Technology Innovation, University of Piemonte Orientale, Alessandria, Italy
Mauro Patrone

Department of Science and Technology Innovation, University of Piemonte Orientale, Alessandria, Italy
Marcello Manfredi

Department of Science and Technology Innovation, University of Piemonte Orientale, Alessandria, Italy
Roberto Guaschino

Transfusion Medicine, “SS. Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria, Italy

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Laura Mazzucco, Valeria Balbo, Simona Martinotti, Elia Ranzato, Mauro Patrone, et al. (2021). Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers, 1(1), 1-6. https://doi.org/10.11648/j.frontiers.20210101.11

Copy | Download

ACS Style

Laura Mazzucco; Valeria Balbo; Simona Martinotti; Elia Ranzato; Mauro Patrone, et al. Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers. 2021, 1(1), 1-6. doi: 10.11648/j.frontiers.20210101.11

Copy | Download

AMA Style

Laura Mazzucco, Valeria Balbo, Simona Martinotti, Elia Ranzato, Mauro Patrone, et al. Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study. Frontiers. 2021;1(1):1-6. doi: 10.11648/j.frontiers.20210101.11

Copy | Download

@article{10.11648/j.frontiers.20210101.11,
  author = {Laura Mazzucco and Valeria Balbo and Simona Martinotti and Elia Ranzato and Mauro Patrone and Marcello Manfredi and Roberto Guaschino},
  title = {Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study},
  journal = {Frontiers},
  volume = {1},
  number = {1},
  pages = {1-6},
  doi = {10.11648/j.frontiers.20210101.11},
  url = {https://doi.org/10.11648/j.frontiers.20210101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.frontiers.20210101.11},
  abstract = {Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component Protein-Enriched Filtered PRP (PEFPRP) obtained through the ultrafiltration of low-concentration PRP and compared these effects with those of a standard PRP and other blood components preparation. Method: PEFPRP is a plasma enriched obtained by ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and other blood components preparation. Result and Conclusion: PEFPRP provides a high concentration of proteins which have an important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Protein-enriched Platelet-Rich Plasma (PEFPRP) a New Products for Tissue Regeneration Developed Through the Ultrafiltration of PRP - Preclinical Study
AU  - Laura Mazzucco
AU  - Valeria Balbo
AU  - Simona Martinotti
AU  - Elia Ranzato
AU  - Mauro Patrone
AU  - Marcello Manfredi
AU  - Roberto Guaschino
Y1  - 2021/01/22
PY  - 2021
N1  - https://doi.org/10.11648/j.frontiers.20210101.11
DO  - 10.11648/j.frontiers.20210101.11
T2  - Frontiers
JF  - Frontiers
JO  - Frontiers
SP  - 1
EP  - 6
PB  - Science Publishing Group
SN  - 2994-7197
UR  - https://doi.org/10.11648/j.frontiers.20210101.11
AB  - Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component Protein-Enriched Filtered PRP (PEFPRP) obtained through the ultrafiltration of low-concentration PRP and compared these effects with those of a standard PRP and other blood components preparation. Method: PEFPRP is a plasma enriched obtained by ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and other blood components preparation. Result and Conclusion: PEFPRP provides a high concentration of proteins which have an important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration.
VL  - 1
IS  - 1
ER  -

Copy | Download